TRIALSITEIQ PUBLIC FEASIBILITY SCORECARD · GRADE C

NCT06836232: An Open-Label Pilot Study of VTX2735 in Recurrent Pericarditis

Sponsor: Zomagen Biosciences Ltd. · Phase: PHASE2 · Area: CARDIOLOGY_METABOLIC · Target Enrollment: 50 pts

Competing Trials Overlap

13 Active Trials

Excess Burn Exposure

$2,357,200

Rescue Site Savings

+$1,560,400

Unlock Full NCT06836232 Backup Super-Site Packet ($49 One-Time Pass)

Download the complete list of top-decile low-cannibalization clinical sites, verified Principal Investigator (PI) direct emails/phones, and protocol optimization benchmarks.

Download $49 NCT06836232 Rescue Dossier →